Locations:
April 4, 2018/Neurosciences

PACNS or RCVS? Differences in Clinical Presentation

How to tell the difference and why it matters

16-RHE-871-Calabrese-Hero-Image-650x450pxl

By Rula Hajj-Ali, MD, and Leonard Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Primary angiitis of the central nervous system (PACNS) is a devastating disease in which exclusive inflammation and destruction of vessels in the CNS cause progressive, debilitating neurological deficits. Prognosis improves greatly with proper treatment, but with nonspecific tests and many confounding mimics, diagnosis can be tricky.

One of PACNS’s closest mimics is reversible cerebral vasoconstriction syndrome (RCVS). The distinguishing characteristic of this group is the “thunderclap” headache — sudden, severe and with or without neurological deficits. Originally, rheumatologists treated RCVS as benign angiopathy of the CNS. In 2007, Calabrese et al set forth RCVS as a concept encompassing several syndromes with unifying clinical, laboratory and radiologic features. The clinical features and diagnostic criteria described in that paper have been considered the standard since its publication.

Distinguishing between RCVS and PACNS is critical because the treatment protocol is so vastly different. Misdiagnosing PACNS as RCVS can deprive a patient of medications that prolong survival and improve outcomes. These conditions are close mimics, but the astute clinician has several tools in her armamentarium to distinguish between them. We offer a brief overview of differences in clinical presentation below. Future posts will discuss differences in test results and management.

chart

Clinical presentation

Patients with PACNS are more commonly male and trend older with a mean age of 50 years at onset, while patients with RCVS are more likely to be female and a bit younger. Patients with both conditions almost always present with headaches, but the differences in onset and type are important to distinguish between the mimics. Patients with PACNS experience subacute onset of headaches with focal and nonfocal deficits; a patient with sudden-onset, severe, “thunderclap” headaches should be considered for RCVS whether or not neurological deficits are present. RCVS is monophasic, but patients with PACNS will experience these symptoms chronically.

Advertisement

When patients present with these symptoms, diagnostic tests can help eliminate the mimics and narrow towards a precise diagnosis.

Dr. Hajj-Ali is Associate Director of the Center for Vasculitis Care and Research in the Department of Rheumatic and Immunologic Diseases. Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology.

Advertisement

Related Articles

rendering of new rehab space
November 12, 2026/Neurosciences/PM&R

New Neurology Building to Feature Revolutionary Rehab Technology

Physical, occupational and speech therapists will provide state-of-the-art outpatient care

mosquito on human skin

Rare New Neuroinvasive Threat Identified for Patients on B Cell-Depleting Therapy

Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies

Head shots of Susan Linder and Karen Green
November 3, 2026/Neurosciences/Podcast

Connecting Neuro Rehab Research and Clinical Care (Podcast)

Advanced technologies are changing expectations about what’s possible

illustration of street entrance to a hospital emergency area

Architecture as a Therapeutic Tool: Acute Stroke Care in Our New Neurological Building

A rare opportunity to design for speed, care coordination, recovery and continuous monitoring

Doctor and hospital tech standing next to an older patient in a hospital bed

Inpatient Program Reduced Medication Errors in Patients With Parkinson’s Disease

Multidisciplinary, proactive approach also improved discharge outcomes

floating CAR T cell against background of other cells

Zola-Cel CAR T-Cell Therapy Shows Promising Initial Results in Multiple Sclerosis

Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

Ad